Keywords: bayer, avigen, sign, million, deal, gene, therapy
Bayer and Avigen sign $60 million deal for gene therapy in hemophilia
Article | 17 November 2000
Bayer AG and US biotechnology company Avigen have forged a deal worth upto $60 million for the latter's Coagulin-B gene therapy ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
